SOURCE Inostics GmbH.. BEAMing DNA blood screening technology detects medication resistance in colorectal cancers patients early Two research published back-to-back again in last week’s Character applied DNA blood tests utilizing the BEAMing technology to detect medication level of resistance mediated by KRAS mutations in colorectal cancers patients weeks before treatment failing was observed. Et al., June 2012] Nature Epub 13., Character Epub 13 June 2012]. Related StoriesViralytics enters into medical trial collaboration contract with MSDNew RNA check of blood platelets may be used to identify area of cancerScientists discover little molecule that may block development of BRCA-deficient tumor cellsBoth teams figured blood-based non-invasive monitoring of patients going through targeted therapy could offer significant benefits by enabling early intervention with extra treatment options that could delay or prevent disease progression.Cardinal Wellness Pharmaceutical segment CEO Jon Giacomin stated that as the healthcare industry proceeds to evolve toward value-based performance versions,MTM services have become an increasingly important toolin the sector’s effort to improve medication adherence and patient outcomes while reducing adverse events and unnecessary healthcare costs over the continuum of care. He also said that MTM solutions play a critical part in enabling payers to boost their Medicare Star Rankings performance and additional quality improvement procedures. Cardinal Wellness launched its ownMTM answer for retail pharmaciesin 2014 – through which Cardinal Health pharmacists deliver MTM solutions to patients, with respect to participating retail pharmacies.